Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07YDN
|
||||
| Former ID |
DNC006615
|
||||
| Drug Name |
ISORHAMNETIN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [531094] | ||
| Formula |
C16H12O7
|
||||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
||||
| InChI |
1S/C16H12O7/c1-22-11-4-7(2-3-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3
|
||||
| InChIKey |
IZQSVPBOUDKVDZ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 3-oxoacyl-[acyl-carrier protein] reductase | Target Info | Inhibitor | [528213] | |
| Cytochrome P450 1B1 | Target Info | Inhibitor | [531094] | ||
| Enoyl-ACP reductase | Target Info | Inhibitor | [528213] | ||
| Reactome | Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Estrogen metabolism | |||||
| Benzo(a)pyrene metabolism | |||||
| Tamoxifen metabolism | |||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Estrogen Receptor Pathway | |||||
| Sulindac Metabolic Pathway | |||||
| Arylhydrocarbon receptor (AhR) signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| miR-targeted genes in adipocytes - TarBase | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
| Ref 528213 | J Med Chem. 2006 Jun 1;49(11):3345-53.Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. | ||||
| Ref 531094 | Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. Epub 2010 Jul 13.Selective inhibition of methoxyflavonoids on human CYP1B1 activity. | ||||